SER-603 / Seres Therap - LARVOL DELTA

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease (GlobeNewswire) - "Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification....In the MiGUT in vitro gut model, which recapitulates patient-derived IBD microbiomes, SER-603 reduced inflammatory cytokine production across multiple samples, supporting its potential to impact disease-relevant biology and providing translational support for its mechanism of action."

Preclinical • Inflammatory Bowel Disease

Seres Therapeutics…Provides Business Updates (GlobeNewswire) - "The Company continues to advance its preclinical stage live biotherapeutic product candidates, including SER-603. The Company is conducting IND-enabling activities for SER-603 and is engaging potential collaborators to support the clinical advancement of this program as a mono- or combination therapy for IBD."

Preclinical • Inflammatory Bowel Disease

Accordingly, the Company's strategy moving forward will prioritize advancing its early-stage programs, including SER-603 that targets inflammatory and immune indications such as ulcerative colitis, Crohn's disease, and immune checkpoint related enterocolitis (irEC). Discussions are ongoing with counterparties related to potential collaborations in these areas. (GlobeNewswire)

Pipeline update • Crohn's disease • Ulcerative Colitis